Metabasis Therapeutics (MBRX) Reports Q2 Loss of $0.34, Beats by 2c
More News related to MBRX
- Trading Outlook for Metabasis Therapeutics Issued by StockPreacher.com
- Ligand Pharmaceuticals (LGND) To Acquire Metabasis Therapeutics (MBRX)
- Ligand to Acquire Metabasis for Cash and Contingent Value Rights
- Metabasis Announces Ligand to Acquire Metabasis for Cash and Contingent Value Rights
- Morning Movers 10/09: SCIL, MBRX, CAGC, AVNR, PSTA, SRZ, ELGX Higher; SPPI, ACOR, LXRX Lower
More News related to Earnings
- Macy's (M) Shows Good Progress, But Not Good Enough
- Universal Security (UUU) Share Trade Higher on Q2 Earnings Report
- American DG Energy (ADGE) Posts Q3 Loss of $0.01, In-Line with Q308
- Global Options (GLOI) Posts Q3 Loss of $0.04, Misses by 4c
- Emerson Radio (MSN) Posts Q2 EPS of $0.12, Tops by 5c
Metabasis Therapeutics (Nasdaq: MBRX) reports a Q2 loss of $0.34, 2 cents better than the analyst estimate of ($0.36). Revenues for the quarter were $700K, versus the consensus of $1.24 million.
Related Categories
EarningsStocks Mentioned
-0.02Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
